ASCENTAGE PHARMA GROUP INTERNATIONAL

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-normalization DCF on a per-ADS basis (1 ADS = 4 ordinary shares): $94.6M TTM revenue base; revenue growth 40%/35%/30%/25%/20% years 1-5 then 10% years 6-10 as the two approved oncology products (olverembatinib, lisaftoclax) scale in China and globally; operating margin improves from -30% currently to a normalized 20% by year 5, held through year 10, as R&D spend falls as a share of revenue; 13% discount rate; 3% terminal growth; approximately -$28M net debt (CNY-denominated balance sheet converted at ~7.1 CNY/USD); 93.31M ADS-equivalent shares outstanding.

Reasoning: Ascentage is a commercial-stage but still loss-making biopharma, so a pure product-revenue DCF with explicit margin normalization (rather than a naive P/E or an unadjusted current-loss extrapolation) better captures the path to profitability as its approved oncology drugs scale; the elevated discount rate reflects China-market regulatory/reimbursement risk plus continued heavy R&D investment.